281 related articles for article (PubMed ID: 20410185)
1. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.
Ross FM; Chiecchio L; Dagrada G; Protheroe RK; Stockley DM; Harrison CJ; Cross NC; Szubert AJ; Drayson MT; Morgan GJ;
Haematologica; 2010 Jul; 95(7):1221-5. PubMed ID: 20410185
[TBL] [Abstract][Full Text] [Related]
2. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
4. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
[TBL] [Abstract][Full Text] [Related]
5. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.
Maura F; Bergsagel PL
Hematol Oncol Clin North Am; 2024 Apr; 38(2):267-279. PubMed ID: 38199896
[TBL] [Abstract][Full Text] [Related]
8. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Mikulasova A; Smetana J; Wayhelova M; Janyskova H; Sandecka V; Kufova Z; Almasi M; Jarkovsky J; Gregora E; Kessler P; Wrobel M; Walker BA; Wardell CP; Morgan GJ; Hajek R; Kuglik P
Eur J Haematol; 2016 Dec; 97(6):568-575. PubMed ID: 27157252
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.
Chi J; Ballabio E; Chen XH; Kušec R; Taylor S; Hay D; Tramonti D; Saunders NJ; Littlewood T; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS; Lawrie CH
Biol Direct; 2011 May; 6():23. PubMed ID: 21592325
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
11. Plasma cell neoplasms and related entities-evolution in diagnosis and classification.
Fend F; Dogan A; Cook JR
Virchows Arch; 2023 Jan; 482(1):163-177. PubMed ID: 36414803
[TBL] [Abstract][Full Text] [Related]
12. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M; Shaughnessy JD
Blood; 2007 Feb; 109(4):1692-700. PubMed ID: 17023574
[TBL] [Abstract][Full Text] [Related]
16. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
17. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Richardson PG; Laubach J; Mitsiades CS; Schlossman RL; Ghobrial IM; Munshi NC; Anderson KC
Oncology (Williston Park); 2011 Jun; 25(7):594, 596. PubMed ID: 21888257
[No Abstract] [Full Text] [Related]
18. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
19. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
Brousseau M; Leleu X; Gerard J; Gastinne T; Godon A; Genevieve F; Dib M; Lai JL; Facon T; Zandecki M;
Clin Cancer Res; 2007 Oct; 13(20):6026-31. PubMed ID: 17947464
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
